


At Risk 228 87 24 3 Events 0 103 148 165



	Male
At Risk	138


Events


Female

At Risk

Events

urviva	Survival time, months					
symptomatic	_	- Male, In bed <50% of the day	Female, Asymptomatic	_	Female,	
	Male, Asymptom	atic				
At Risk	36	18	6	1		
Events	0	13	24	28		
	Male, Symptoma	itic and ambulatory				
At Risk	71	20	5	1		
Events	0	39	51	54		
	Male, In bed <50	% of the day				
At Risk	29	6	2	0		
Events	0	22	26	28		
	Male, In bed > 50	0% of the day				
At Risk	1	0	0	0		
Events	0	1	1	1		
	Female, Asympto	omatic				
At Risk	27	13	2	0		
Events	0	4	8	9		
	Female, Sympton	matic and ambulatory				
At Risk	42	23	8	1		
Events	0	12	22	28		
	Female, In bed <	:50% of the day				
At Risk	21	7	1	0		
Events	0	11	15	16		






	Male			
At Risk	138	44	13	2
CUM EVENTS	0	76	103	112


Female

At Risk	90	43	11	1
CUM EVENTS	0	27	45	53

urviva	Survival time, months				
, Asymptomatic	_	Male, In bed <50% of the day	— Female, Asymptomatic		— Fema
,	Male, Asymp	tomatic			
At Risk	36	18	6	1	
CUM EVENTS	0	13	24	28	
	Male, Sympto	omatic and ambulatory			
At Risk	71	20	5	1	
CUM EVENTS	0	39	51	54	
	Male, In bed	<50% of the day			
At Risk	29	6	2	0	
CUM EVENTS	0	22	26	28	
	Male, In bed	> 50% of the day			
At Risk	1	0	0	0	
CUM EVENTS	0	1	1	1	
	Female, Asyr	mptomatic			
At Risk	27	13	2	0	
CUM EVENTS	0	4	8	9	
	Female, Sym	ptomatic and ambulatory			
At Risk	42	23	8	1	
CUM EVENTS	0	12	22	28	
	Female, In be	ed <50% of the day			
At Risk	21	7	1	0	
CUM EVENTS	0	11	15	16	



N RISK




1	Male			
CUM EVENTS	138	44	13	2
N RISK	0	76	103	112

Female		
CUM EVENTS	90	

EVENTS 90	90	43	11	1	
N RISK	0	27	45	53	

urviva	Survival time, months				
, Asymptomatic	-	Male, In bed <50% of the day	— Female, Asymptomatic		— Fema
,	Male, Asym	ntomatic			
CLIMA EVENITO	-		0	4	
CUM EVENTS N RISK	36 0	18 13	6 24	1 28	
N KISK	U	13	24	20	
	Male, Symp	tomatic and ambulatory			
CUM EVENTS	71	20	5	1	
N RISK	0	39	51	54	
	Male, In be	d <50% of the day			
CUM EVENTS	29	6	2	0	
N RISK	0	22	26	28	
	Male, In be	d > 50% of the day			
CUM EVENTS	1	0	0	0	
N RISK	0	1	1	1	
	Female, As	ymptomatic			
CUM EVENTS	27	13	2	0	
N RISK	0	4	8	9	
	Female, Sy	mptomatic and ambulatory			
CUM EVENTS	42	23	8	1	
N RISK	0	12	22	28	
	Female In I	ped <50% of the day			
CUM EVENTS	21	7	1	0	
N RISK	0	<i>1</i>	15	16	
14 KIOK	U		10	10	



	Male
At Risk	138


Events

Female


At Risk

Events


urviva	Survival time, months					
symptomatic	_	- Male, In bed <50% of the day	Female, Asymptomatic	_	Female,	
	Male, Asymptom	atic				
At Risk	36	18	6	1		
Events	0	13	24	28		
	Male, Symptoma	itic and ambulatory				
At Risk	71	20	5	1		
Events	0	39	51	54		
	Male, In bed <50	% of the day				
At Risk	29	6	2	0		
Events	0	22	26	28		
	Male, In bed > 50	0% of the day				
At Risk	1	0	0	0		
Events	0	1	1	1		
	Female, Asympto	omatic				
At Risk	27	13	2	0		
Events	0	4	8	9		
	Female, Sympton	matic and ambulatory				
At Risk	42	23	8	1		
Events	0	12	22	28		
	Female, In bed <	:50% of the day				
At Risk	21	7	1	0		
Events	0	11	15	16		




At Risk 228 87 24 3 Events 0 103 148 165



At Risk 227 87 24 3 Events 0 102 147 218






At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24


Drug A

Drug B

At Risk	102	102	95	75	55	0
Events	0	0	4	17	26	33

<u>e</u> 8:4 £	1	5	10	15	1	
Cumulative In	0	5	Months to Dea		20	25
S		_	Drug A, I — Drug	a A, II — Drug A,	III	
			Drug B, I — Drug			
[Drug A, I					
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
[Orug B, I					
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
[Orug A, II					
At Risk	32	32	30	27	23	0
Events	0	0	1	2	3	5
[Orug B, II					
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
[Orug A, III					
At Risk	31	30	29	26	16	0
Events	0	0	1	1	7	10
[Orug B, III					
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12






— Diag A — Diag E


At Risk	98	97	94	83	61	0
CUM EVENTS	0	0	2	7	17	24

Drug B
100

Drug A

At Risk	102	102	95	75	55	0
CUM EVENTS	0	0	4	17	26	33






At Risk	98	97	94	83	61	0
Events	0	0	2	7	17	24

Drug A


Drug B

At Risk	102	102	95	75	55	0
Events	0	0	4	17	26	33


<u>e</u> 8:4 £	1	5	10	15	1	
Cumulative In	0	5	Months to Dea		20	25
S		_	Drug A, I — Drug	a A, II — Drug A,	III	
			Drug B, I — Drug			
[Drug A, I					
At Risk	35	35	35	30	22	0
Events	0	0	0	4	7	9
[Orug B, I					
At Risk	33	33	33	28	23	0
Events	0	0	0	3	5	9
[Orug A, II					
At Risk	32	32	30	27	23	0
Events	0	0	1	2	3	5
[Orug B, II					
At Risk	36	36	32	23	17	0
Events	0	0	2	8	12	12
[Orug A, III					
At Risk	31	30	29	26	16	0
Events	0	0	1	1	7	10
[Orug B, III					
At Risk	33	33	30	24	15	0
Events	0	0	2	6	9	12





At Risk 200 199 189 158 116 0 Events 0 0 6 24 43 57



At Risk	200	199	189	158	116	0
Events	0	0	6	24	43	57







At Risk 228 87 24 3 Events 0 103 148 165